Table 2 Individual subset predictive value: ROC analysis and cut-off for patients’ stratification as high-risk of progression.
Normalised Naive | Normalised Treg | IRC | Risk-Score | ||
|---|---|---|---|---|---|
At-risk participants n = 158 | AUC (range) | 0.313 (0.212–0.413) | 0.330 (0.227–0.432) | 0.313 (0.212–0.413) | 3 subsets |
P | 0.001 | 0.003 | 0.001 | 02-Mar | |
Cut-off | −10% | −3% | 4% | 93% | |
Specificity | 80% | 82% | 80% | 36.50% | |
Sensitivity | 41% | 35% | 41% | 4.95 | |
OR | 1.95 | 2.3 | 1.95 | 74% | |
PPV | 61% | 64% | 61% | 71.50% | |
NPV | 63% | 63% | 63% | ||
Evolving IA n = 294 | AUC (range) | 0.363 (0.281–0.446) 0.001 | 0.389 (0.307–0.471) | NA | 2 subsets |
P | −10% | 0.01 | Absent/Present | ||
Cut-off | 92% | −3% | 80% | ||
Specificity | 51% | 83% | 69% | ||
Sensitivity | 6.4 | 21% | 3.38 | ||
OR | 84% | 1.5 | 83% | ||
PPV | 69% | 80% | 64% | ||
NPV | 29.5 | ||||
MTX-induced Remission n = 120 | AUC (range) | 0.822 (0.710–0.933) | NA | NA | Naive subset only |
P | <0.0001 | ||||
Cut-off | 2.50% | ||||
Specificity | 81% | ||||
Sensitivity | 78% | ||||
OR | 15.4 | ||||
PPV | 78% | ||||
NPV | 81% | ||||
Remission/ Flare n = 145 | AUC (range) | 0.271 (0.151–0.389) <0.0001 | NA | NA | Naive subset only |
P | −2.50% | ||||
Cut-off | 77% | ||||
Specificity | 62% | ||||
Sensitivity | 2.7 | ||||
OR | 43% | ||||
PPV | 88% | ||||
NPV | |||||
